Relapsing-remitting multiple sclerosis (RRMS) – to reduce the frequency of clinical exacerbations of the disease and reduce the risk of progression of disability.
– Clinical study results show a continuous reduction in the incidence of multiple sclerosis exacerbations and a slowdown in brain atrophy in patients receiving Gilenya continuously for 4.5 years.
– A decrease in the frequency of exacerbations of MS and improvement in MRI parameters are observed in patients already at the stage of a clinical trial.
– Study results indicate that once-daily oral Gilenya has the best combination of safety and tolerability.
Active ingredient: fingolimod